Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyad144
Keywords
rare cancer; neuroendocrine neoplasm; gastrointestinal stromal tumor; carcinosarcoma; primary malignant melanoma of esophagus
Categories
Ask authors/readers for more resources
Esophageal cancer is a common disease worldwide with various histological subtypes. Rare esophageal cancers, such as neuroendocrine neoplasm and gastrointestinal stromal tumor, have different treatment strategies due to their distinct biological features. Limited evidence is available for these rare cancers. Neuroendocrine neoplasm, gastrointestinal stromal tumor, carcinosarcoma, and malignant melanoma each require specific treatment approaches. Primary malignant melanoma of the esophagus is resistant to cytotoxic chemotherapy but may respond to immune checkpoint inhibitors.
Esophageal cancer is common worldwide, including in Japan, and its major histological subtype is squamous cell carcinoma. However, there are some rare esophageal cancers, including neuroendocrine neoplasm, gastrointestinal stromal tumor, carcinosarcoma and malignant melanoma. The biological and clinical features of these cancers differ from those of esophageal squamous cell carcinoma. Therefore, different treatment strategies are needed for these cancers but are based on limited evidence. Neuroendocrine neoplasm is mainly divided into neuroendocrine tumor and neuroendocrine carcinoma by differentiation and the Ki-67 proliferation index or mitotic index. Epidemiologically, the majority of esophageal neuroendocrine neoplasms are neuroendocrine carcinoma. The treatment of neuroendocrine carcinoma is similar to that of small cell lung cancer, which has similar morphological and biological features. Gastrointestinal stromal tumor is known to be associated with alterations in the c-KIT and platelet-derived growth factor receptor genes and, if resectable, is treated in accordance with the modified Fletcher classification. Carcinosarcoma is generally resistant to both chemotherapy and radiotherapy and requires multimodal treatments such as surgery plus chemotherapy to achieve cure. Primary malignant melanoma is resistant to cytotoxic chemotherapy, but immune checkpoint inhibitors have recently demonstrated efficacy for malignant melanoma of the esophagus. This review focuses on the current status and future perspectives for rare cancer of the esophagus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available